Viridans group streptococci in febrile neutropenic cancer patients: what should we fear?

Abstract

In this issue of Clinical Infectious Diseases, Shelburne et al report their development and validation of a clinical prediction model for β-lactam resistance in viridans group streptococci (VGS) causing bloodstream infection (BSI) and offer guidance for the use of vancomycin (or gram-positive spectrum antibiotics) for empiric therapy of febrile neutropenia… (More)
DOI: 10.1093/cid/ciu264

Topics

Cite this paper

@article{Freifeld2014ViridansGS, title={Viridans group streptococci in febrile neutropenic cancer patients: what should we fear?}, author={Alison G. Freifeld and Raymund Rabe Razonable}, journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America}, year={2014}, volume={59 2}, pages={231-3} }